Novel therapies for renal cell carcinoma - an update

被引:11
作者
Fishman, M [1 ]
Antonia, S [1 ]
机构
[1] Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA
关键词
immunotherapy; renal cancer; review tutorial; targeted therapy;
D O I
10.1517/13543784.12.4.593
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article reviews the recent progress in the search for new treatments for renal cell cancer (RCC), based on a variety of preclinical models or strategies. Some recent clinical trials addressing migrating treatments from other cancers onto RCC and novel agents are discussed, as well as the molecular targets for some of the novel agents. Drugs oriented to histologically definable RCC features, such as the G250 antigen, and the receptor tyrosine kinases, such as epidermal growth factor receptor, are reviewed. Drugs aimed at antiangiogenesis and perturbing features of the cell cycle are also mentioned, including preclinical and empirical experience. Molecular techniques in the study of von Hippel Lindau-related pathways and mRNA expression analyses are cited. Within the immune model of therapy, progress in the application of immune-related drugs including older cytokines (IL-2, IFN-alpha) and of newer cytokine-variant and other cytokines are discussed. Finally, cell-based therapies such as lymphocyte infusions, tumour-cell vaccines, dendritic cell vaccines and allogeneic mini-transplant are outlined. Although high percentage improvements in outcomes for metastatic RCC are not yet realised, the many fronts for scientific and clinical advances form some basis for optimism in the coming years.
引用
收藏
页码:593 / 609
页数:17
相关论文
共 147 条
[1]   Development of the proteasome inhibitor PS-341 [J].
Adams, J .
ONCOLOGIST, 2002, 7 (01) :9-16
[2]   Interleukin-2 and histamine dihydrochloride in metastatic melanoma [J].
Agarwala, SS ;
Hellstrand, K ;
Naredi, P .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3558-3559
[3]   Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma [J].
Agarwala, SS ;
Glaspy, J ;
O'Day, SJ ;
Mitchell, M ;
Gutheil, J ;
Whitman, E ;
Gonzalez, R ;
Hersh, E ;
Feun, L ;
Belt, R ;
Meyskens, F ;
Hellstrand, K ;
Wood, D ;
Kirkwood, JM ;
Gehlsen, KR ;
Naredi, P .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :125-133
[4]   Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer [J].
Almand, B ;
Clark, JI ;
Nikitina, E ;
van Beynen, J ;
English, NR ;
Knight, SC ;
Carbone, DP ;
Gabrilovich, DI .
JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :678-689
[5]  
AMATO R, 2002, P AM SOC CLIN ONC
[6]  
Amato RJ, 2000, SEMIN ONCOL, V27, P177
[7]  
Ananth S, 1999, CANCER RES, V59, P2210
[8]  
Antonia SJ, 2002, J UROL, V167, P1995
[9]   IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma:: long-term results of a controlled randomized clinical trial [J].
Atzpodien, J ;
Kirchner, H ;
Illiger, HJ ;
Metzner, B ;
Ukena, D ;
Schott, H ;
Funke, PJ ;
Gramatzki, M ;
von Jürgensom, S ;
Wandert, T ;
Patzelt, T ;
Reitz, M .
BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1130-1136
[10]  
Béliveau R, 2002, CLIN CANCER RES, V8, P1242